NewsRoom Articles - Page 59 of 144 - PsychedelicNewsWire (PNW)

WednesdayFeb 09, 2022 1:48 pm

Study Uses Linguistic Analysis to Find Differences in Effects of Psychedelic Experiences

A new study looked into the various types of subjective experiences produced by five types of psychedelic drugs. Using computer algorithms, the researchers conducted an analysis of thousands of reports on the effects of psychedelic substances that were anonymously published. Research has shown that psychedelic substances, including psilocybin and MDMA, possess the potential to treat psychiatric conditions such as PTSD and depression. While various studies have shown that these drugs cause changes in an individual’s consciousness and perception, minimal research has been conducted quantifying the experiences linked to the consumption of these drugs. Adrian Hase, a postdoctoral researcher at the…

TuesdayFeb 08, 2022 3:49 pm

MAPS Is Developing Training Program on How to Deal with Bad Psychedelic Trips

Psychedelics sometimes cause bad trips by creating horrible scenarios for some individuals. Rick Doblin, the founder of the Multidisciplinary Association for Psychedelic Studies (“MAPS”), recently talked about difficult trips and how people could be guided through these experiences. During a recent interview, Doblin, a psychonaut and veteran psychedelic researcher, was asked whether MAPS would start a psychonaut training program based partly on principles of psychedelic harm reduction. Doblin revealed that the program, which was briefly referenced on the MAP’s website, was still being developed but would launch in various parts of North America where psychedelic substances had been decriminalized. He…

TuesdayFeb 08, 2022 12:05 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Marks a Major Step in Seamless Phase 2/3 Smoking Cessation Clinical Trial; Partners with Combat Stress to Treat PTSD among Veterans

Mydecine has summitted a pre-IND briefing package to the FDA in readiness for its phase 2/3 smoking cessation trial scheduled for Q2 2022 The study will be led by Dr. Matthew Johnson, with the placebo-controlled research being conducted at Johns Hopkins University Mydecine also announced its partnership with Combat Stress to use psilocybin in a psychoactive-assisted psychotherapy PTSD treatment program for veterans Combat Stress will also be one of several sites for the company’s upcoming clinical trials set to launch later in the year Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) plans to launch its seamless phase 2/3 smoking cessation…

MondayFeb 07, 2022 2:09 pm

New Study Finds Weak Link Between Symptoms of Psychosis, Psychedelic Use

A new study has found that individuals who consume psychedelic substances are more likely to report symptoms associated with psychosis, which can be explained by the use of other psychoactive drugs and the presence of other mental health disorders. Psychedelics are drugs that can alter an individual’s cognition, mood and perception. This class of drugs produces hallucinogenic effects when used. Common psychedelics include psilocybin and LSD. Scientific studies conducted in the recent past have found evidence showing the possible therapeutic effects of these substances. However, few studies have looked into the potential harmful psychological effects associated with the use of…

FridayFeb 04, 2022 2:48 pm

Oregon Legislators File Bill to Ensure Psilocybin Equity

Legislators in the state of Oregon have introduced a bicameral initiative that will establish a 15-member group that will focus on psilocybin health equity. The task force will be made up of representatives of the indigenous community, individuals with experience with psychedelic treatment, regulators involved in psilocybin reform implementation and legislators. This comes as the state prepares to implement its first legal psilocybin services program. The measure, which was introduced by Rep. Wlnsvey Campos and Sen. Lawrence Spence, stipulates that the task force will be responsible for ensuring accessibility and equity in the state’s developing psilocybin services. The group will…

ThursdayFeb 03, 2022 2:57 pm

Colorado Campaigners File Modified Measures to Establish Psychedelic Healing Centers

Activists in the state of Colorado recently filed amended versions of two ballot measures that would establish licensed healing centers where individuals can use psilocybin for therapeutic purposes and legalize psilocybin. Legislators in the state also introduced a separate measure requiring that research into the effectiveness of plant-based psychedelic substances be conducted. The two 2022 ballot initiatives were filed by Veronica Perez, an entrepreneur, and Kevin Matthews, the campaign manager behind the 2019 vote to locally decriminalize psilocybin in Denver. The measures are similar to earlier versions activists filed with the office of the secretary of state in December, excluding…

ThursdayFeb 03, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Expanding Wellness Clinics’ Reach to Communities Where Access to Life-Changing Mental Health Treatments is Limited

Tens of millions of Americans live in areas where mental health providers are scarce Delic is working on making psychedelic-based treatments more accessible and affordable In 2021, the company acquired Ketamine Infusion Centers (“KIC”) and Ketamine Wellness Centers, becoming the owner and operator of the largest chain of wellness clinics administering ketamine treatments in the U.S. A May 2021 CNBC article exploring the cost and accessibility of mental health care in the United States noted that the number of Americans experiencing depression and anxiety had increased – a total of 42% of U.S. adults had reported symptoms, up from 11%…

WednesdayFeb 02, 2022 2:24 pm

Study Finds Psilocybin Can Be Safely Administered Without Adverse Effects

A new study conducted by researchers at the Institute of Psychiatry, Psychology & Neuroscience has found that psilocybin can be administered safely to six participants at the same time, at doses of either 25 mg or 10 mg. Psilocybin is a naturally occurring hallucinogenic compound found in certain mushrooms that grow in Mexico, South America, Europe and the United States. The research has demonstrated the viability and safety of psilocybin for use in controlled settings in combination with therapy as a possible treatment for various mental health disorders, including post-traumatic stress disorder and treatment-resistant depression. The treatments currently used to…

WednesdayFeb 02, 2022 12:39 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Clinical LOI to Further Use of Psychedelic Therapeutics in Treating Mental Illnesses

Canadian-based mental health treatment-focused biotechnology company Mydecine Innovations Group has been advancing research on the use and improvement of compounds found in nature, particularly the psychedelic psilocybin compound Mydecine recently announced an LOI with The Newly Institute to use Mydecine’s psilocybin and MDMA for treatment at The Newly’s mental health clinics nationwide The LOI is the first collaboration under Mydecine’s SASSP program, which will provide psychedelic drug products and related services to physicians, clinics and hospitals in Canada for psychotherapy Health Canada announced earlier this month that the government has amended its medicinal regulations to allow psilocybin and MDMA prescriptions…

TuesdayFeb 01, 2022 2:19 pm

Training Gets Underway for Crucial Psychedelic Clinical Trial

Recently, psychotherapist training for a psychedelic clinical trial that is being led by Beckley Psytech began. This comes as interest in psychedelic substances and the properties and benefits they possess increases in America as well as the United Kingdom. Beckley Psytech specializes in addressing psychiatric and neurological disorders through new applications for psychedelic drugs. The pioneering phase 2 clinical trial will explore 5-MeO-DMT assisted psychotherapy in the management of treatment-resistant depression. Psychedelic-assisted psychotherapy refers to the therapeutic process entailing the administration of a psychedelic drug alongside traditional talk-therapy sessions. Prior clinical trials have demonstrated that psychedelic-assisted psychotherapy improves clinical symptoms…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050